ASX Linkedin Twitter               

 

Scientific Presentations 2017

 

Presentation Title Conference Date
Activity of a novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients previously treated with anti-PD1 blockade therapy 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago IL USA 05 June 2016

Hall A – Poster Board 109 (8:00-11:30am).

Poster presentation held in Hall D1 (4:45-6:00pm)

Keynote-200 phase 1b: A novel combination study of intravenously delivered Coxsackievirus A21 and pembrolizumab in advanced cancer patients 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago IL USA 05 June 2016

Hall A – Poster Board 194b (8:00-11:30am)

Phase 1b study of intratumoral Coxsackievirus A21 (CVA21) and systemic pembrolizumab in advanced melanoma patients: Interim results of the CAPRA clinical trial American Association for Cancer Research (AACR) Annual Meeting 2017, Washington DC USA 3 April 2017
The MITCI (Phase 1b) study: A novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients with or without previous immune checkpoint therapy treatment American Association for Cancer Research (AACR) Annual Meeting 2017, Washington DC USA 4 April 2017
Phase 1b KEYNOTE-200 (STORM study): A study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients American Association for Cancer Research (AACR) Annual Meeting 2017, Washington DC USA 4 April 2017

 

Viralytics Limited
Suite 305, Level 3, 66 Hunter Street
Sydney NSW 2000 Australia
T: +61 (0)2 9988 4000 F: +61 (0)2 8068 6038

© Viralytics Limited 2017
This information does not take your circumstances into account. Read the relevant ASX releases, financial reports and prospectuses before making an investment decision. Shares in Viralytics Limited, ABN 12 010 657 351, are traded on the Australian Stock Exchange (ASX:VLA) and on the over-the-counter market (OTC: VRACY).